Literature DB >> 35967168

Covaxin-Induced Lymphocytic Myocarditis.

Nitish Mittal1, Dushyant Pawar2, Kanak Parmar2, Zhaunn Sly3, Gaspar Del Rio-Pertuz2, Mohammad M Ansari3, Nandini Nair3.   

Abstract

We report the case of a young adult male with endomyocardial biopsy-proven lymphocytic myocarditis following Covaxin administration. Covaxin differs from the mRNA vaccines in that it is an inactivated virus developed using the whole virion inactivated using the Vero cell platform. We successfully managed the patient with complete resolution of symptoms.
Copyright © 2022, Mittal et al.

Entities:  

Keywords:  covid-19; covid-19 vaccination myocarditis; endomyocardial biopsy; heart failure; vaccine

Year:  2022        PMID： 35967168      PMCID： PMC9365502          DOI： 10.7759/cureus.26759

Source DB:  PubMed          Journal:  Cureus        ISSN： 2168-8184


  13 in total

Review 1.  Coxsackievirus myocarditis.

Authors:  N R Rose; D A Neumann; A Herskowitz
Journal:  Adv Intern Med       Date:  1992

2.  Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.

Authors:  Alida L P Caforio; Sabine Pankuweit; Eloisa Arbustini; Cristina Basso; Juan Gimeno-Blanes; Stephan B Felix; Michael Fu; Tiina Heliö; Stephane Heymans; Roland Jahns; Karin Klingel; Ales Linhart; Bernhard Maisch; William McKenna; Jens Mogensen; Yigal M Pinto; Arsen Ristic; Heinz-Peter Schultheiss; Hubert Seggewiss; Luigi Tavazzi; Gaetano Thiene; Ali Yilmaz; Philippe Charron; Perry M Elliott
Journal:  Eur Heart J       Date:  2013-07-03       Impact factor: 29.983

Review 3.  Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases.

Authors:  P Noel Barrett; Sara J Terpening; Doris Snow; Ronald R Cobb; Otfried Kistner
Journal:  Expert Rev Vaccines       Date:  2017-07-27       Impact factor: 5.217

4.  Myocarditis secondary to smallpox vaccination.

Authors:  Kyle Keinath; Tyler Church; Benjamin Kurth; Edward Hulten
Journal:  BMJ Case Rep       Date:  2018-03-22

Review 5.  Covaxin: An overview of its immunogenicity and safety trials in India.

Authors:  Rohit Sharma; Swati Tiwari; Aparna Dixit
Journal:  Bioinformation       Date:  2021-10-31

Review 6.  Cardiac Adverse Events after Vaccination-A Systematic Review.

Authors:  Kanak Parmar; Sai Subramanyam; Gaspar Del Rio-Pertuz; Pooja Sethi; Erwin Argueta-Sosa
Journal:  Vaccines (Basel)       Date:  2022-04-29

7.  Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.

Authors:  Raches Ella; Siddharth Reddy; Harsh Jogdand; Vamshi Sarangi; Brunda Ganneru; Sai Prasad; Dipankar Das; Dugyala Raju; Usha Praturi; Gajanan Sapkal; Pragya Yadav; Prabhakar Reddy; Savita Verma; Chandramani Singh; Sagar Vivek Redkar; Chandra Sekhar Gillurkar; Jitendra Singh Kushwaha; Satyajit Mohapatra; Amit Bhate; Sanjay Rai; Samiran Panda; Priya Abraham; Nivedita Gupta; Krishna Ella; Balram Bhargava; Krishna Mohan Vadrevu
Journal:  Lancet Infect Dis       Date:  2021-03-08       Impact factor: 25.071

8.  A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination.

Authors:  Renata J M Engler; Michael R Nelson; Limone C Collins; Christina Spooner; Brian A Hemann; Barnett T Gibbs; J Edwin Atwood; Robin S Howard; Audrey S Chang; Daniel L Cruser; Daniel G Gates; Marina N Vernalis; Marguerite S Lengkeek; Bruce M McClenathan; Allan S Jaffe; Leslie T Cooper; Steve Black; Christopher Carlson; Christopher Wilson; Robert L Davis
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

Review 9.  Myocarditis With COVID-19 mRNA Vaccines.

Authors:  Biykem Bozkurt; Ishan Kamat; Peter J Hotez
Journal:  Circulation       Date:  2021-07-20       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.